Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review

Abstract

Simple Summary Pancreatic cancer is one of the most aggressive forms of cancer, and in the majority of cases involves a mutation in the RAS gene, a protein which, when activated, stimulates tumour growth. Inhibiting this protein has long been a challenge, and previous drugs were effective against only one rare type of mutation. In August 2026, a new oral drug called daraxonrasib was approved, as it is capable of blocking the active form of RAS across multiple mutation types, offering hope to a greater number of patients. This review brings together the available data from clinical trials on the efficacy and safety of daraxonrasib in patients whose pancreatic cancer has progressed following prior treatment. The results show that daraxonrasib prolonged survival, slowed disease progression and led to tumour shrinkage more frequently than chemotherapy, whilst causing mainly mild, manageable side effects. These results confirm that daraxonrasib is a promising new drug and also highlight areas where further research is still needed, particularly with regard to rarer types of mutations.